KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.96

Dosimetry-guided peptide receptor radionuclide therapy in neuroendocrine tumors: interim safety analysis of the DUONEN trial.

Maciej Kolodziej, Marta Opalinska, Renata Mikolajczak, Alicja Hubalewska-Dydejczyk, Marek Dedecjus, Aldona Kowalska, Marek Saracyn, Piotr Garnuszek, Izabela Cieszykowska, Joanna Januszkiewicz-Caulier, Joanna Dlugosinska, Adam Daniel Durma, Katarzyna Jozwik-Plebanek, Adrianna Mroz, Katarzyna Janiak, Danuta Gasior-Perczak, Malgorzata Trofimiuk-Muldner, Anna Sowa-Staszczak, Janusz Braziewicz, Wioletta Lenda-Tracz, Krzysztof Kacperski, Anna Budzynska, Agata Kubik, Patrycja Pastusiak, Wioletta Chalewska, Anna Borkowska, Paulina Cegla, Agata Walecka-Mazur, Artur Szczodry, Grzegorz Kaminski

Front Endocrinol (Lausanne) 16 1716247

PMID41404513
PMCIDPMC12702747
DOI10.3389/fendo.2025.1716247
发表日期2025-12-17
入排依据:主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。
已检查 7 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other;Figure 5:AI 判定为 other;另有 2 张未列出。
摘要

摘要

BACKGROUND: PRRT with [177Lu]Lu-DOTA-TATE improves survival in advanced GEP-NETs, but fixed-activity dosing may result in undertreatment or unnecessary toxicity. Individualized dosimetry and tandem-PRRT with 90Y/177Lu have been proposed, but prospective randomized evidence is lacking. METHODS: DUONEN is an ongoing multicenter, randomized phase 3 trial (N = 92 planned; 56 analyzed) comparing standard fixed-activity [177Lu]Lu-DOTA-TATE (arm A) with three dosimetry-guided regimens: arm B (177Lu+90Y, variable 90Y); arm C (177Lu+90Y, variable 177Lu); arm D (variable 177Lu). Organ dosimetry was performed after each cycle, with per-cycle activity modifications to respect kidney (23 Gy) and marrow (2 Gy) thresholds. Safety was assessed by laboratory, renal, and hepatic parameters. RESULTS: Activity reductions predominated in arms B and C, while increases were common in arm D. Median cumulative kidney and marrow doses were highest in arm C (29.1 Gy and 0.79 Gy, respectively), driven by 90Y contribution. Hematologic declines were observed across all arms, most prominently in lymphocytes and platelets, and correlated with marrow dose but not with categorical dose modifications. Renal function remained stable, and no clinically relevant hepatotoxicity occurred. CONCLUSIONS: This interim analysis demonstrates the feasibility and safety of dosimetry-guided PRRT strategies, including individualized 177Lu escalation and tandem 90Y/177Lu. DUONEN provides the first randomized prospective evidence for isotope- and patient-tailored PRRT dosing. Long-term follow-up will clarify their impact on efficacy. CLINICAL TRIAL REGISTRATION: https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-006068-99, identifier 2020-006068-99.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(7,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1 Modification patterns by study arm. Bar chart showing the proportion of patients with increased, decreased, or unchanged isotope activities in arms (B-D) . By protocol, [ 90 Y] was modulated in arm (B) and [ 177 Lu] in arms (C, D) , while the complementary isotope was kept constant. The majority of patients in arms (B, C) experienced activity reductions, whereas dose increases predominated in arm (D) .
非 KM Figure
Figure 2Figure 2 (A) Cumulative kidney dose by arm. Box-and-whisker plots (with jittered individual values) showing cumulative absorbed kidney doses (Gy) across arms A–D . Median kidney dose was lowest in arm A (fixed-activity [ 177 Lu]) and highest in arm C (dosimetry-guided [ 177 Lu] + fixed-activity [ 90 Y]). (B) Cumulative marrow dose by arm. Box-and-whisker plots (with jittered individual values) showing cumulative absorbed marrow doses (Gy) across arms A–D . Median marrow dose was lowest in arm A and highest in arm C .
非 KM Figure
Figure 3Figure 3 Correlation between Δ[ 177 Lu] activity and kidney dose in arm C. Scatter plot showing the relationship between mean change in administered [ 177 Lu] activity (post-baseline vs. baseline) and cumulative kidney dose (Gy) in arm C. A significant negative correlation was observed, indicating the predominant role of [ 90 Y] in determining kidney exposure.
非 KM Figure
Figure 4Figure 4 Hemoglobin change at V4 by arm. Box-and-whisker plots (with jittered individual values) showing change in hemoglobin concentration (g/dL) at V4 relative to baseline (T1). A modest but consistent decline was observed across all arms.
非 KM Figure
Figure 5Figure 5 Neutrophil change at V4 by arm. Box-and-whisker plots (with jittered individual values) showing change in neutrophil count (×10 9 /L) at V4 relative to baseline (T1). Declines were observed in all arms, consistent with transient hematologic toxicity.
非 KM Figure
Figure 6Figure 6 Lymphocyte nadir vs. cumulative marrow dose. Scatter plot showing the correlation between nadir lymphocyte count (Δ vs. T1) and cumulative marrow dose (Gy). A moderate negative correlation was identified (Spearman ρ≈−0.49), indicating that greater marrow exposure was associated with deeper lymphocyte declines.
非 KM Figure
Figure 7Figure 7 eGFR change at V4 by arm. Box-and-whisker plots (with jittered individual values) showing change in estimated glomerular filtration rate (mL/min/1.73 m²) at V4 relative to baseline (T1). No clinically significant differences were observed between arms.
非 KM Figure